Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma

Abstract

Prolyl 4‑hydroxylase beta polypeptide (P4HB) is a chaperone protein associated with temozolomide (TMZ) resistance through the unfolded protein response. Cancer cells with constitutive activation of endoplasmic reticulum stress and upregulation of P4HB have been observed to show resis‑ tance against chemotherapies. The present study focused on the evaluation of the prognostic value of P4HB in subtypes of glioma with or without O6‑methylguanine‑DNA methyltrans‑ ferase (MGMT) promoter methylation. P4HB expression was assessed by immunohistochemical staining in 73 grade I‑IV gliomas and its association with the clinicopathological data was determined. It was indicated that P4HB expression was significantly associated with several parameters, including age, tumour grade and the number of TMZ treatment cycles received. In the Kaplan‑Meier analysis, P4HB expression was positively associated with risk of mortality and disease progression. In patients treated with TMZ, high P4HB expres‑ sion was significantly associated with poor overall survival (OS) and progression‑free survival (PFS). The association between MGMT promoter methylation and P4HB expression was also assessed. Patients with MGMTMethP4HBLow tumours had the most favourable PFS (48 months) among cases with various combinations of MGMT methylation status and P4HB expression. Multivariate analysis revealed that P4HB may be used as an independent prognostic indicator of OS, particu‑ larly in high‑grade gliomas. The present study uncovered the potential role of P4HB in a nuanced pathological stratification during clinical decision‑making with respect to MGMT promoter methylation status and TMZ treatment.